{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:18Z","timestamp":1793945598964,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clml.2023.03.010","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:45:24Z","timestamp":1679629524000},"page":"515-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenish S.","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande H.","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnadozie","family":"Emechebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kamalakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-5860","authenticated-orcid":false,"given":"Alexandros","family":"Rampotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Skarbnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey E.","family":"Roeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-644X","authenticated-orcid":false,"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Alhasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pivneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Burne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-0812","authenticated-orcid":false,"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2023.03.010_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2016.52.4.2470954","article-title":"Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia","volume":"52","author":"Del Poeta","year":"2016","journal-title":"Drugs Today (Barc)"},{"issue":"7","key":"10.1016\/j.clml.2023.03.010_bib0002","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clml.2015.02.019","article-title":"Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice","volume":"15","author":"Sanford","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2023.03.010_bib0003","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/13543784.2017.1386173","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Gentile","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.clml.2023.03.010_bib0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000510768","article-title":"Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs","volume":"144","author":"Smolewski","year":"2021","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2016.1.128","article-title":"Sequencing of chronic lymphocytic leukemia therapies","volume":"2016","author":"Barrientos","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.clml.2023.03.010_bib0006","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.010_bib0007","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1200\/EDBK_159018","article-title":"Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination?","volume":"35","author":"Brown","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.03.010_bib0009","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/asheducation-2017.1.354","article-title":"Safety profiles of novel agent therapies in CLL","volume":"2017","author":"Ahn","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.03.010_bib0011","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/EDBK_238735","article-title":"Tailored treatment strategies for chronic lymphocytic leukemia in a rapidly changing era","volume":"39","author":"Brander","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.clml.2023.03.010_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.03.010_bib0013","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14656566.2016.1168401","article-title":"Chronic lymphocytic leukemia therapy: new targeted therapies on the way","volume":"17","author":"Vitale","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2023.03.010_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2695","article-title":"Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on","volume":"38","author":"Molica","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.03.010_bib0016","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"Forum","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2023.03.010_bib0017","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cancers13061336","article-title":"Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance","volume":"13","author":"F\u00fcrstenau","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.clml.2023.03.010_bib0018","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.03.010_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2023.03.010_bib0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.010_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.clml.2023.03.010_bib0022","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2023.03.010_bib0023","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2023.03.010_bib0024","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.03.010_bib0025","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.010_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S202286","article-title":"Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis","volume":"10","author":"Nuttall","year":"2019","journal-title":"J Blood Med"},{"issue":"35","key":"10.1016\/j.clml.2023.03.010_bib0027","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2023.03.010_bib0028","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1182\/blood-2018-99-119015","article-title":"Treatment patterns and outcomes of patients with CLL treated with chemoimmuno-and novel agent-based therapy: a multicenter study","volume":"132","author":"Mato","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2023.03.010_bib0030","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.03.010_bib0031","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.16271","article-title":"The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia","volume":"188","author":"Eyre","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0032","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.clml.2023.03.010_bib0033","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1002\/cncr.29605","article-title":"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia","volume":"121","author":"Short","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.03.010_bib0034","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","author":"Shanafelt","year":"2015","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/asheducation-2017.1.212","article-title":"Fixed duration vs continuous therapy in multiple myeloma","volume":"2017","author":"Ludwig","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2023.03.010_bib0036","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.024","article-title":"Relapsed\/refractory chronic lymphocytic leukemia: chemoimmunotherapy, treatment until progression with mechanism-driven agents or finite-duration therapy?","volume":"11","author":"Cuneo","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"12","key":"10.1016\/j.clml.2023.03.010_bib0037","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2023.03.010_bib0038","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:45Z","timestamp":1761871305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2152265023001076"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}